BridgeMD
Randomized, open-label, single dose, three-period, three treatment cross-over bioavailability study comparing test products Rosuvastatin/Ezetimibe, tablets, 20 mg /10 mg or Ezehron Duo, 20 mg + 10 mg, tablet, both administered in combination with Nilemdo 180 mg film-coated tablets to reference products Nustendi 180 mg/10 mg film-coated tablets in combination with Crestor, 20 mg, film-coated tablets in healthy male and female subjects under fasting conditions.
EU CTIS ID: 2023-507048-35-00
What this study is testing
To evaluate the pharmacokinetic properties and to compare the bioavailability of rosuvastatin and total ezetimibe after administration of formulation in Treatment A and in Treatment C versus Treatment B.
- Human Pharmacology (Phase I)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Healthy males and non-pregnant and non-breast-feeding females1, ≥18 and ≤ 60 years of age (on the day of Informed Consent Form signing). Caucasian race.
- Non-smoker or past smoker (who has stopped smoking at least 6 months before the first dosing).
- Body Mass Index (BMI) ≥ 18.5 and ≤ 30.0 kg/m2, (on the day of screening).
- Subject is available for the whole study and has provided his/her written informed consent.
- Subjects in good health, as determined by screening medical history, physical examination, vital signs assessments (heart rate, systolic and diastolic blood pressure, and body temperature) and 12-lead ECG. Minor deviations outside the reference ranges will be acceptable, if deemed not clinically significant by the Investigator
- All laboratory screening results within the normal range or deemed clinically insignificant by Investigator
You likely can't join if
- Acute or chronic diseases and/or clinical finding which may interfere with the aims of the study or with the drug’s safety, tolerability, bioavailability and/or pharmacokinetics of the IMP.
- Body temperature is out of the range of 35.7-36.9 °C at screening and at check-in.
- Sitting blood pressure after a minimum of 5 minutes of rest is out of the range of 90-140 mmHg for systolic BP and/or 60-90 mmHg for diastolic BP and/or heart rate out of the range of 50-100 bpm during the screening procedure.
- Existing gastrointestinal diseases, renal or hepatic diseases and/or pathological findings, which might interfere with the drug’s safety, tolerability, absorption and/or pharmacokinetics.
- Any significant clinical abnormality, including a positive result of HBsAg and/or HCV and/or HIV test during screening procedure.
- Anaemia, haemoglobin below 120 g/L for women and 130 g/L for men at screening.
See the full eligibility criteria
Who can join
- Healthy males and non-pregnant and non-breast-feeding females1, ≥18 and ≤ 60 years of age (on the day of Informed Consent Form signing). Caucasian race.
- Non-smoker or past smoker (who has stopped smoking at least 6 months before the first dosing).
- Body Mass Index (BMI) ≥ 18.5 and ≤ 30.0 kg/m2, (on the day of screening).
- Subject is available for the whole study and has provided his/her written informed consent.
- Subjects in good health, as determined by screening medical history, physical examination, vital signs assessments (heart rate, systolic and diastolic blood pressure, and body temperature) and 12-lead ECG. Minor deviations outside the reference ranges will be acceptable, if deemed not clinically significant by the Investigator
- All laboratory screening results within the normal range or deemed clinically insignificant by Investigator
- Acceptance of use of contraceptive measures during the whole study by both female and male subjects2.
- The subject speaks and understands Czech fluently.
What rules you out
- Acute or chronic diseases and/or clinical finding which may interfere with the aims of the study or with the drug’s safety, tolerability, bioavailability and/or pharmacokinetics of the IMP.
- Body temperature is out of the range of 35.7-36.9 °C at screening and at check-in.
- Sitting blood pressure after a minimum of 5 minutes of rest is out of the range of 90-140 mmHg for systolic BP and/or 60-90 mmHg for diastolic BP and/or heart rate out of the range of 50-100 bpm during the screening procedure.
- Existing gastrointestinal diseases, renal or hepatic diseases and/or pathological findings, which might interfere with the drug’s safety, tolerability, absorption and/or pharmacokinetics.
- Any significant clinical abnormality, including a positive result of HBsAg and/or HCV and/or HIV test during screening procedure.
- Anaemia, haemoglobin below 120 g/L for women and 130 g/L for men at screening.
- Positive result of blood pregnancy test at screening or positive urine pregnancy test at check-in or breast-feeding or lack of results of pregnancy test.
- Less than 45 days between exit procedure in previous study and the first dosing in this study.
- History or presence of serious clinical illness that can impact the fate of drugs (their absorption and/or distribution and/or metabolism and/or elimination).
- History or severe allergy or allergic reactions to the study drugs or related drugs (e.g. ACE, dihydropyridine derivates) or any of the excipients.
- Clinically significant illness within 28 days before the first dosing, including major surgery.
- Use of systemic drugs known to alter hepatic metabolism within 90 days prior to the first dosing.
- Serious mental disease and/or inability to cooperate with clinical team.
- Orthostatic hypotension in history or during the screening procedure.
- Drug, alcohol (≥ 40 g pure ethanol per day for men or ≥ 20 g pure ethanol per day for women), solvents or caffeine abuse.
- Use of organ-toxic drugs within 90 days before the first dosing (e.g. any drug with a well-defined potential for toxicity to a major organ or system such as chloramphenicol, which may cause bone marrow suppression).
- Active liver disease and/or level of ALT, AST or GGT ≥ 3 x ULN at the screening.
- Creatine kinase (CK) out of normal range unless evaluated by Investigator as non-significant for inclusion in the study.
- Impaired kidney function, clearance of creatinine (MDRD) < 1 mL/s.
- Current or history of skeletal muscles disorders (muscular toxicity, myopathy and rhabdomyolysis) or current skeletal muscles injuries, including a family history of hereditary muscular disorders.
- History or presence of lactose intolerance, galactose intolerance or glucose-galactose malabsorption syndrome.
- Current or history of hypothyreosis.
- Any systemic prescription treatment within 28 days before the first dosing, except hormonal contraceptives or substitution taken without significant changes in dose for 90 days prior to the first dosing.
- Current or history of hyperuricemia or gout.
- Inability to swallow large tablet.
- Any systemic over-the-counter (OTC) drug treatment and/or vitamins and/or herbal treatment (e.g. Saint John´s Wort) and/or food supplements within 14 days before the first dosing.
- Donation or loss of at least 500 mL of blood within 90 days or donation of plasma or platelets within 14 days before the first dosing.
- Getting a tattoo, body piercing or any cosmetic treatment involving skin penetration within 90 days before the screening unless evaluated by Investigator as non-significant for inclusion in the study.
- Positive results of drugs of abuse in urine at screening and at check-in.
- Positive result of alcohol breath test at screening and at check-in.
- Positive result of urine cotinine test at screening.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.